Compare McCormick & Company, Incorporated (MKC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Summit Therapeutics Inc — how do they compare? McCormick & Company, Incorporated trades at $44.81 (market cap $12.39B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: McCormick & Company, Incorporated and Summit Therapeutics Inc are close in size by market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Summit Therapeutics Inc for 16 Days on average.
| MKC | SMMT | |
|---|---|---|
Market Cap | $12.39B | $13.71B |
Volume | 6,140,872 | 6,173,057 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $26.38 |
52-Week Low | $44.14 | $12.43 |
Typical Hold Time | 67 Days | 16 Days |
Enterprise Value | $17.07B | $13.04B |
Dividend Yield | 4.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick (MKC) trades at $44.81, down 0.97% on the day, with a bearish technical signal and neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with EPS of $0.86, driven by margin expansion and the McCormick de Mexico acquisition. Revenue grew 17% in constant currency, and the full-year outlook was reaffirmed. Valuation ratios appear attractive with a P/E of 8.31 and net income margin of 19.39%, while cash flow trends show improvement in 2026.
The outlook is mixed; fundamentals are solid with earnings beats and dividend growth, but technicals and analyst sentiment lean cautious. Upside exists if execution continues, yet risks include integration challenges and macroeconomic pressures. The consensus price target of $53.50 implies potential appreciation, but near-term volatility may persist.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
